ORAGENICS INC

NYSE: OGEN (Oragenics Inc.)

Last update: 23 Oct, 12:13AM

0.405

-0.01 (-1.82%)

Previous Close 0.413
Open 0.407
Volume 20,396
Avg. Volume (3M) 28,578
Market Cap 1,828,696
Price / Book 0.250
52 Weeks Range
0.400 (-1%) — 1.34 (230%)
Earnings Date 7 Aug 2025 - 11 Aug 2025
Diluted EPS (TTM) -30.60
Total Debt/Equity (MRQ) 1,855.20%
Current Ratio (MRQ) 1.04
Operating Cash Flow (TTM) -7.65 M
Levered Free Cash Flow (TTM) -5.58 M
Return on Assets (TTM) -170.96%
Return on Equity (TTM) -748.05%

AIStockmoo Score

-4.4
High debt. Weak profitability. Thin short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Return on Capital info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Downtrend over the past year. Far below its 52-week high. info
In a downtrend: the price is below its moving averages, and they are falling. It has dropped well below them. Volume is heavier on up days. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Holdings' Sentiment info NA
News Mood info NA
Insider Activity info NA
Institutional Flow info NA
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Earnings per share have gone up and down. Made a loss in recent years. info
Below its medium-term trend line. info
Price is low against its 52-week average. Down over 5 years. info
Trend down on all three terms. Short-term momentum falling. info
Price is near resistance. info
Final Score -4.36
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Oragenics Inc. - -

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
OGEN 2 M - - 0.250 -4.4
CYBN 359 M - - - 0.0
NRXS 60 M - - 18.58 -1.2
CVM 21 M - - 2.22 -3.7
NHWK 20 M - - 0.260 0.0
AEON 10 M - - - -3.3

Select this tab to load the latest available analysis.

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Sector Healthcare
Industry Biotechnology
% Held by Insiders 12.11%
% Held by Institutions 1.02%

Ownership

Name Date Shares Held
25 Llc 30 Sep 2026 23,160
St. Johns Investment Management Company, Llc 30 Jun 2026 1,924
Adkins Seale Capital Management Llc 30 Jun 2026 3
Ameritas Advisory Services, Llc 30 Jun 2026 0

No data within this time range.

No data within this time range.

Technical Setup Medium

Trend order
Slope
Entry –
Volume
In a downtrend: the price is below its moving averages, and they are falling. It has dropped well below them. Volume is heavier on up days.
Nearest support: 0.161 – 0.179 · moderate level
Nearest resistance: 0.341 – 0.359 · moderate level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria